Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer The important question of whether to recommend risk-reducing surge
Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer
The important question of whether to recommend risk-reducing surgery to patients who are carriers of pathogenic mutations in either BRCA1 or BRCA2 genes (or both), and have already developed breast cancer, has been investigated in a study from Italy reported at the 2025 San Antonio Breast Cancer Symposium.
Researcher Matteo Lambertini MD PhD, from the University of Genoa, Assistant Professor and Consultant in Medical Oncology at the San Martino IST Hospital in Genoa, Italy, gave the details to Audio Journal of Oncology correspondent Peter Goodwin.
SABCS ABSTRACT TITLE:
“Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study”
Related Episodes
Hope S. Rugo, MD; SABCS 2025: Selective Estrogen Degrader Giredestrant Brings Clinically Meaningful Improvements in Metastatic Breast Cancer: evERA Breast Cancer Trial
Hope S. Rugo, MD, discusses the Phase III evERA Breast Cancer trial at SABCS 2025, revealing clinically meaningful improvements with giredestrant plus everolimus for ER-positive, HER2-negative metastatic breast cancer previously treated with a CDK4/6 inhibitor. Subgroup analyses show benefits regard
Thorsten Kühn MD PhD; SABCS 2025: No Need for Axillary Node Dissection When Clinically Node-Positive Breast Cancers Convert to Node-Negative After Neoadjuvant Chemotherapy
Thorsten Kühn MD PhD discusses findings from the AXSANA/EUBREAST 3(R) study at SABCS 2025. The research indicates that breast cancer patients who convert from clinically node-positive to node-negative after neoadjuvant chemotherapy do not require axillary lymph node dissection. Less invasive surgical staging procedures were found to be non-inferior in terms of three-year outcomes, irrespective of tumor type or initial stage.
Erika Hamilton MD; 2025 SABCS: Small Molecule HER2 Inhibitor Tucatinib Improves Progression Free Survival in Patients with HER2-positive Metastatic Breast Cancer: in HER2CLIMB-05 Trial
This episode features an interview with Erika Hamilton MD at the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Hamilton discusses findings from the HER2CLIMB-05 trial, showing that adding tucatinib to trastuzumab and pertuzumab significantly improves progression-free survival in patients with HER2-positive metastatic breast cancer as first-line maintenance therapy, with no new safety signals. This small molecule HER2 inhibitor offers a promising new option.